Anti-Apolipoprotein A-1 IgG Predict All-Cause Mortality and Are Associated with Fc Receptor-Like 3 Polymorphisms
Open Access
- 18 April 2017
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 8, 437
Abstract
Background: Autoantibodies against apolipoprotein A-1 (anti-apoA-1 IgG) have emerged as an independent biomarker for cardiovascular disease and mortality. However, their association with all-cause mortality in the community as well as their possible genetic determinants have not been studied. Objective: To determine whether anti-apoA-1 IgG: a) predict all-cause mortality in the general population, and b) are associated with single–nucleotide polymorphisms (SNPs) in a genome-wide association study (GWAS). Methods: Clinical, biological and genetic data from the population-based, prospective CoLaus study, including 5220 participants (mean age 52.6 years, 47.3% men) followed over a median duration of 5.6 years. The primary study outcome was all-cause mortality. Results: After multivariate adjustment, anti-apoA-1 IgG positivity independently predicted all-cause mortality: hazard ratio (HR)=1.54, 95% Confidence Interval (95%CI): (1.11-2.13), P=0.01. A dose-effect relationship was also observed, each standard deviation of logarithmically transformed anti-apoA-1 IgG being associated with a 15% increase in mortality risk: HR=1.15, 95%CI: (1.02-1.28), P=0.028. The GWAS yielded 9 SNPs belonging to the Fc receptor like-3 (FCRL3) gene that were significantly associated with anti-apoA-1 IgG levels, with the lead SNP (rs6427397, P=1.54×10-9) explaining 0.67% of anti-apoA-1 IgG level variation. Conclusion: Anti-apoA-1 IgG levels a) independently predict all-cause mortality in the general population and b) are linked to FCRL3, a susceptibility gene for numerous autoimmune diseases. Our findings indicate that preclinical autoimmunity to anti-apoA-1 IgG may represent a novel mortality risk factor.Keywords
Funding Information
- Fondation Leenaards
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (3200B0–105993, 3200B0-118308, 33CSCO-122661, 33CS30-139468 and 33CS30-148401, 310030-163335, 31003A-143914)
- Seventh Framework Programme (FP7-INNOVATION I HEALTH-F2-2013-602114; Athero-B-Cell: Targeting and exploiting B cell function for treatment in cardiovascular disease)
This publication has 49 references indexed in Scilit:
- Genome-Wide Association Analysis of Autoantibody Positivity in Type 1 Diabetes CasesPLOS Genetics, 2011
- Differential Genetic Associations for Systemic Lupus Erythematosus Based on Anti–dsDNA Autoantibody ProductionPLOS Genetics, 2011
- Genetic Basis of Autoantibody Positive and Negative Rheumatoid Arthritis Risk in a Multi-ethnic Cohort Derived from Electronic Health RecordsThe American Journal of Human Genetics, 2011
- Autoimmune‐mediated reduction of high‐density lipoprotein–cholesterol and paraoxonase 1 activity in systemic lupus erythematosus–prone gld miceArthritis & Rheumatism, 2010
- Expression of the Autoimmune Susceptibility Gene FcRL3 on Human Regulatory T Cells Is Associated with Dysfunction and High Levels of Programmed Cell Death-1The Journal of Immunology, 2010
- High-density lipoprotein inversely relates to its specific autoantibody favoring oxidation in thrombotic primary antiphospholipid syndromeLupus, 2010
- The FCRL3 −169CT promoter single‐nucleotide polymorphism, which is associated with systemic lupus erythematosus in a Japanese population, predicts expression of receptor protein on CD19+ B cellsArthritis & Rheumatism, 2009
- The CoLaus study: a population-based study to investigate the epidemiology and genetic determinants of cardiovascular risk factors and metabolic syndromeBMC Cardiovascular Disorders, 2008
- Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variantsNature Genetics, 2007
- Mortality Excess in Individuals with Elevated IgA Anti-Transglutaminase Antibodies: The KORA/MONICA Augsburg Cohort Study 1989–1998European Journal of Epidemiology, 2006